Toll-like Receptor 2 as a Marker Molecule of Advanced Ovarian Cancer

Biomolecules. 2021 Aug 13;11(8):1205. doi: 10.3390/biom11081205.

Abstract

Ovarian cancer is a global problem that affects women of all ages. Due to the lack of effective screening tests and the usually asymptomatic course of the disease in the early stages, the diagnosis is too late, with the result that less than half of the patients diagnosed with ovarian cancer (OC) survive more than five years after their diagnosis. In this study, we examined the expression of TLR2 in the peripheral blood of 50 previously untreated patients with newly diagnosed OC at various stages of the disease using flow cytometry. The studies aimed at demonstrating the usefulness of TLR2 as a biomarker in the advanced stage of ovarian cancer. In this study, we showed that TLR2 expression levels were significantly higher in women with more advanced OC than in women in the control group. Our research sheds light on the prognostic potential of TLR2 in developing new diagnostic approaches and thus in increasing survival in patients with confirmed ovarian cancer.

Keywords: TLR2; Toll-like receptor; biomarker; expression; ovarian cancer; receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers, Tumor / blood
  • Carcinoma, Ovarian Epithelial* / diagnosis
  • Carcinoma, Ovarian Epithelial* / metabolism
  • Case-Control Studies
  • Female
  • Humans
  • Middle Aged
  • Ovarian Neoplasms* / diagnosis
  • Ovarian Neoplasms* / metabolism
  • Prognosis
  • Toll-Like Receptor 2 / blood*

Substances

  • Biomarkers, Tumor
  • TLR2 protein, human
  • Toll-Like Receptor 2